Values First Advisors, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Values First Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	BUY	$83.14 - $145.99 $215,083 - $377,676	2,587 Added 59.93%	6,904 $1.01 Million
Q1 2022 May 03, 2022	BUY	$110.08 - $142.92 $34,675 - $45,019	315 Added 7.87%	4,317 $512,000
Q4 2021 Mar 10, 2022	BUY	$99.73 - $148.48 $399,119 - $594,216	4,002 New	4,002 $552,000
Q3 2021 Nov 15, 2022	SELL	$98.85 - $138.91 $277,867 - $390,476	-2,811 Reduced 40.72%	4,093 $569,000
Q2 2021 Nov 15, 2022	BUY	$65.78 - $105.02 $56,176 - $89,687	854 Added 15.15%	6,491 $630,000
Q1 2021 Nov 15, 2022	SELL	$64.07 - $91.75 $81,176 - $116,247	-1,267 Reduced 18.35%	5,637 $385,000
Q4 2020 Nov 15, 2022	BUY	$65.07 - $98.24 $5,791 - $8,743	89 Added 1.86%	4,869 $417,000
Q3 2020 Nov 15, 2022	SELL	$59.04 - $77.95 $111,880 - $147,715	-1,895 Reduced 28.39%	4,780 $311,000
Q2 2020 Nov 15, 2022	SELL	$29.01 - $74.23 $6,643 - $16,998	-229 Reduced 3.32%	6,675 $488,000
Q1 2020 Jan 09, 2023	BUY	$27.51 - $57.29 $222,968 - $464,335	8,105 New	8,105 $276 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.